According to a research report released by Morgan Stanley, Cinda Biotech's product revenue for the first half of the year was RMB 8.2 billion, raising the 2026-2028 product revenue/total revenue forecast by 6%/5%/2%, which mainly reflects the strong performance of core products such as GLP-1, PCSK9 and cooperative products. The corresponding change in earnings forecast per share during the period was +13.7%/+11.2%/-1.2%. The target price was raised from HK$135 to HK$138.5, with an “increase in weight” rating.

According to a research report released by Morgan Stanley, Cinda Biotech's product revenue for the first half of the year was RMB 8.2 billion, raising the 2026-2028 product revenue/total revenue forecast by 6%/5%/2%, which mainly reflects the strong performance of core products such as GLP-1, PCSK9 and cooperative products. The corresponding change in earnings forecast per share during the period was +13.7%/+11.2%/-1.2%. The target price was raised from HK$135 to HK$138.5, with an “increase in weight” rating.